Quick Answer
Zentalis Pharmaceuticals, Inc. reported Net Income Loss of -$137.06 million for the year ending 2025.
- Zentalis Pharmaceuticals, Inc. showed an increase of +17.4% in Net Income Loss from 2024 to 2025.
- This data is from Zentalis Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$8.34 million | Q2 2019: -$10.47 million | Q3 2019: -$12.34 million | Q4 2019: -$14.51 million | Q1 2020: -$16.13 million | Q2 2020: -$26.86 million | Q3 2020: -$34.56 million | Q4 2020: -$40.30 million | Q1 2021: -$49.90 million | Q2 2021: -$54.57 million | Q3 2021: -$4.19 million | Q4 2021: -$50.06 million | Q1 2022: -$59.08 million | Q2 2022: -$68.36 million | Q3 2022: -$54.40 million | Q1 2023: -$63.22 million | Q2 2023: -$112.53 million | Q3 2023: -$55.53 million | Q1 2024: $10.07 million | Q2 2024: -$88.28 million | Q3 2024: -$40.16 million | Q1 2025: -$48.28 million | Q2 2025: -$26.87 million | Q3 2025: -$26.69 million.
- Over the full 7 years of available data (2019 to 2025), Zentalis Pharmaceuticals, Inc.'s Net Income Loss has declined by 200.2%.
- Historical annual values: Fiscal year 2025: -$137.06 million | Fiscal year 2024: -$165.84 million | Fiscal year 2023: -$292.19 million | Fiscal year 2022: -$236.81 million | Fiscal year 2021: -$158.73 million | Fiscal year 2020: -$117.84 million | Fiscal year 2019: -$45.66 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: